Cadrenal Therapeutics (NASDAQ:CVKD) Price Target Cut to $13.00 by Analysts at HC Wainwright

Cadrenal Therapeutics (NASDAQ:CVKD) had its target price lowered by HC Wainwright from $32.00 to $13.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Cadrenal Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Stock Performance

Shares of NASDAQ CVKD opened at $4.32 on Tuesday. The company’s fifty day moving average price is $6.50 and its 200 day moving average price is $9.20. Cadrenal Therapeutics has a 1 year low of $4.21 and a 1 year high of $17.50. The company has a market capitalization of $10.84 million, a PE ratio of -0.65 and a beta of 1.53.

Cadrenal Therapeutics (NASDAQ:CVKD) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.24). On average, equities analysts expect that Cadrenal Therapeutics will post -7.59 EPS for the current year.

Institutional Investors Weigh In On Cadrenal Therapeutics

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. acquired a new stake in shares of Cadrenal Therapeutics in the third quarter valued at about $103,000. Geode Capital Management LLC raised its position in shares of Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Cadrenal Therapeutics in the third quarter valued at about $274,000. Finally, DRW Securities LLC acquired a new stake in shares of Cadrenal Therapeutics in the fourth quarter valued at about $171,000. 7.92% of the stock is currently owned by institutional investors and hedge funds.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.